The Investigation of Oxidative Stress Parameters in Patients with Lipoid Proteinosis

Öz

Objective: This study aims to investigate the role of oxidative stress in pathogenesis of Lipoid Proteinosis (LP) by measuring the parameters of serum oxidative stress such as total antioxidant status (TAS), total oxidant status (TOS), advanced oxidation protein products (AOPP), oxidative stress index (OSI), ferric reducing antioxidant power (FRAP), lipid hydroperoxide (LOOH) and total free sulfhydryl groups (Total-SH).

Materials and Methods: Fourteen patients with LP diagnosed clinically, radiologically and histopathologically and 14 sex-, age- and body mass index- matched healthy volunteers were included in this prospective case-control study. Serum TAS, TOS, AOPP, FRAP, LOOH and Total-SH were measured spectrophotometrically and OSI were calculated.

Results: Cases with LP had significantly lower serum levels of TAS, FRAP and Total –SH (p< 0.001, for each) and higher levels of OSI, AOPP and LOOH (p= 0.001, p= 0.018, and p= 0.047, respectively). Serum TOS levels were higher in the LP group when compared to that of the control group, but it was not statistically significant (p= 0.081). ROC analysis demonstrated that TAS, FRAP, Total-SH and OSI levels independently predicted LP with strong sensitivity and specificity.

Conclusion: Our results demonstrate that decreased levels of antioxidant parameters and increased levels of oxidant parameters might be used as an ancillary laboratory tests in the diagnosis of LP disease.

Anahtar Kelimeler

• Lipoid Proteinosis,Oxidative Stress,Antioxidant

Lipoid Proteinozis Hastalarında Oksidatif Stres Parametrelerinin Araştırılması

Öz

Amaç: Bu çalışmadaki amacımız, total antioksidan seviye (TAS), ferrik iyon indirgeyici antioksidan güç (FRAP) ve toplam serbest sülfhidril grupları (Total-SH) gibi antioksidan parametreler ile total oksidan seviye (TOS), ileri oksidasyon protein ürünleri (AOPP), oksidatif stres indeksi (OSI) ve lipid hidroperoksit (LOOH) gibi oksidasyon parametrelerini ölçerek Lipoid Proteinozlu (LP) hastalarda oksidatif stresin rolünü araştırmaktır.

Materyal ve Metod: Bu prospektif vaka kontrol çalışmasına klinik, radyolojik ve histopatolojik olarak tanı konulan 14 LP hastası ve cinsiyet, yaş ve vücut kitle indeksi benzer 14 sağlıklı gönüllü katılımcı dahil edildi. Serum TAS, TOS, AOPP, FRAP, LOOH ve Total-SH seviyeleri spektrofotometrik olarak ölçüldü ve OSI değeri hesaplandı.

Bulgular: LP'li hastalarda serum TAS, FRAP ve Total –SH (p< 0,001; her biri için) seviyeleri daha yüksek bulunurken OSI, AOPP ve LOOH düzeyleri daha düşük (sırasıyla, p= 0,001, p= 0,018 ve p= 0,047) bulundu. LP hastalarında serum TOS seviyeleri kontrol grubuna göre daha yüksekti, ancak bu yükseklik istatistiksel olarak anlamlı değildi (p= 0,081). Yapılan ROC analizinde TAS, FRAP, Total-SH ve OSI seviyelerinin LP hastalığını güçlü bir duyarlılık ve yüksek bir özgüllük ile öngördüğünü gösterdi.

Sonuç: LP hastalığının tanısında, antioksidan parametrelerindeki azalma ve oksidan parametrelerindeki artmanın yardımcı laboratuvar testleri olarak kullanılabileceğini göstermektedir.

Anahtar Kelimeler

• Lipoid Proteinozis,Oksidatif Stres,Antioksidan

Kaynakça

1. Bai X, Liu J-W, Ma D-L. Novel mutations in extracellular matrix protein 1 gene in a Chinese patient with Lipoid Proteinosis. Chinese Medical Journal. 2016;129(22):2765‑6.
2. Dertlioglu SB, Çalik M, Çiçek D. Demographic, clinical, and radiologic signs and treatment responses of lipoid proteinosis patients: A 10-case series from Sanliurfa. International Journal of Dermatology. 2014;53(4):516-23.
3. Gao D, Ma X, Lian P, Zhou S, Chen J. Pathogenetic mechanism of lipoid proteinosis caused by mutation of the extracellular matrix protein 1 gene. Molecular Medicine Reports. 2018;17(6):8087-90.
4. Fujimoto N, Terlizzi J, Aho S, Brittingham R, Fertala A, Oyama N, et al. Extracellular matrix protein 1 inhibits the activity of matrix metalloproteinase 9 through high-affinity protein/protein interactions. Experimental Dermatology. 2006;15(4):300-7.
5. Djordjevic D, Jakovljevic V, Cubrilo D, Zlatkovic M, Zivkovic V, Djuric D. Coordination between nitric oxide and superoxide anion radical during progressive exercise in elite soccer players. The Open Biochemistry Journal. 2010;4:100‑6.
6. Aslan M, Horoz M, Sabuncu T, Celik H, Selek S. Serum paraoxonase enzyme activity and oxidative stress in obese subjects. Polskie Archiwum Medycyny Wewnetrznej. 2011;121(6):181‑6.
7. Ates I, Ozkayar N, Altay M, Yilmaz FM, Topcuoglu C, Alisik M, et al. Is disulphide / thiol ratio related to blood pressure in masked hypertension? Clinical and Experimental Hypertension. 2015;38(2):150-4.
8. Manna P, Jain SK. Obesity, oxidative stress, adipose tissue dysfunction, and the associated health risks: Causes and therapeutic strategies. Metabolic Syndrome and Related disorders. 2015;13(10):423‑44.

9. Balci H, Genc H, Papila C, Can G, Papila B, Yanardag H, et al. Serum lipid hydroperoxide levels and paraoxonase activity in patients with lung, breast, and colorectal cancer. Journal of Clinical Laboratory Analysis. 2012;26(3):155-60.
10. Uyanikoglu H, Hilali NG, Yardimciel M, Koyuncu I. A new biomarker for the early diagnosis of ovarian torsion: SCUBE-1. Clinical and Experimental Reproductive Medicine. 2018;45(2):94.
11. Aktepe N, Kocyigit A, Yukselten Y, Taskin A, Keskin C, Celik H. Increased DNA damage and oxidative stress among silver jewelry workers. Biological Trace Element Research. 2015;164(2):185‑91.
12. Altindag O, Gur A, Calgan N, Soran N, Celik H, Selek S. Paraoxonase and arylesterase activities in fibromyalgia. Redox Report. 2007;12(3):134-8.
13. Erel O. A novel automated method to measure total antioxidant response against potent free radical reactions. Clinical Biochemistry. 2004;37(2):112‑9.
14. Erel O. A new automated colorimetric method for measuring total oxidant status. Clinical Biochemistry. 2005;38(12):1103‑11.
15. Witko-Sarsat V, Friedlander M, Capeillere-Blandin C, Nguyen-Khoa T, Nguyen AT, Zingraff J, et al. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney International. 1996;49(5):1304-13.
16. Benzie IFF, Strain JJ. Ferric reducing / antioxidant power assay: Direct measure of total antioxidant activity of biological fluids and modified version for simultaneous measurement of total antioxidant power and ascorbic acid concentration. 1999;299:15-27.
17. Nourooz-Zadeh J. Ferrous ion oxidation in presence of xylenol orange for detection of lipid hydroperoxides in plasma. Methods in Enzymology. 1998;300:58-62.
18. Ellman GL. Tissue sulfhydryl groups. Archives of Biochemistry and Biophysics. 1959;82(1):70-7.
19. Hu ML, Louie S, Cross CE, Motchnik P, Halliwell B. Antioxidant protection against hypochlorous acid in human plasma. The Journal of Laboratory and Clinical Medicine. 1993;121(2):257-62.
20. Oguz Akarsu E, Dincsoy Bir F, Baykal C, Tasdemir V, Kara B, Bebek N, et al. The characteristics and long-term course of epilepsy in lipoid proteinosis: A spectrum from mild to severe seizures in relation to ECM1 mutations. Clinical EEG and Neuroscience. 2018;49(3):192-6.
21. Youssefian L, Vahidnezhad H, Daneshpazhooh M, Abdollahzadeh S, Talari H, Khoshnevisan A, et al. Lipoid proteinosis: Phenotypic heterogeneity in Iranian families with c.507delT mutation in ECM1. Experimental Dermatology. 2015;24(3):220-2.
22. Gunduz O, Sahiner N, Atasoy P, Senyucel C. Acitretin Treatment for Lipoid Proteinosis. Case Reports in Dermatological Medicine. 2012.
23. Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovascular Research. 2009;69(3):562-73.
24. Yabluchanskiy A, Ma Y, Iyer RP, Hall ME, Lindsey ML. Matrix Metalloproteinase-9: Many shades of function in cardiovascular disease. Physiology. 2013;28(6):391-403.
25. Kelly PJ, Morrow JD, Ning MM, Koroshetz W, Lo EH, Terry E, et al. Oxidative stress and matrix metalloproteinase-9 in acute ischemic stroke: The Biomarker Evaluation for Antioxidant Therapies in Stroke (BEAT-Stroke) study. Stroke. 2008;39(1):100-4.
26. Aksoy M, Celik H. Dynamic thiol / disulphide homeostasis in vitiligo patients. Advances in Dermatology and Allergology. 2018;35(5):498‑501.
27. Ersoy MA, Selek S, Celik H, Erel O, Kaya MC, Savas HA, et al. Role of oxidative and antioxidative parameters in etiopathogenesis and prognosis of panic disorder. International Journal of Neuroscience. 2008;118(7):1025‑37.
28. Pandey KB, Rizvi SI. Resveratrol may protect plasma proteins from oxidation under conditions of oxidative stress in vitro. Journal of the Brazilian Chemical Society. 2010;21(5):909-13.
29. Song Y, Liu J, Qiu Z, Chen D, Luo C, Liu X, et al. Advanced oxidation protein products from the follicular microenvironment and their role in infertile women with endometriosis. Experimental and Therapeutic Medicine. 2018;15(1):479-86.
30. Horoz M, Bolukbas C, Bolukbas FF, Sabuncu T, Aslan M, Sarifakiogullari S, et al. Measurement of the total antioxidant response using a novel automated method in subjects with nonalcoholic steatohepatitis. BMC Gastroenterology. 2005;5(1):35.
31. Benzie IFF, Strain JJ. The ferric reducing ability of plasma (FRAP) as a measure of antioxidant power: The FRAP assay. Analytical Biochemistry. 1996;239(1):70-6.
32. Kundi H, Ates I, Kiziltunc E, Cetin M, Cicekcioglu H, Neselioglu S, et al. A novel oxidative stress marker in acute myocardial infarction; Thiol/disulphide homeostasis. American Journal of Emergency Medicine. 2015;33(11):1567‑71.